Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test.
PPI test
meta-regression
sensorimotor gating
systematic review
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
pubmed:
9
6
2020
medline:
26
10
2021
entrez:
8
6
2020
Statut:
ppublish
Résumé
Prepulse inhibition (PPI) of startle is an operational measure of sensorimotor gating that is often impaired in patients with schizophrenia. Despite the large number of studies, there is considerable variation in PPI outcomes reported. We conducted a systematic review and meta-analysis investigating PPI impairment in patients with schizophrenia compared with healthy control subjects, and examined possible explanations for the variation in results between studies. Major databases were screened for observational studies comparing healthy subjects and patients with schizophrenia for the prepulse and pulse intervals of 60 and 120 ms as primary outcomes, ie, PPI-60 and PPI-120. Standardized mean difference (SMD) and 95% confidence intervals (CI) were extracted and pooled using random effects models. We then estimated the mean effect size of these measures with random effects meta-analyses and evaluated potential PPI heterogeneity moderators, using sensitivity analysis and meta-regressions. Sixty-seven primary studies were identified, with 3685 healthy and 4290 patients with schizophrenia. The schizophrenia group showed reduction in sensorimotor gating for both PPI-60 (SMD = -0.50, 95% CI = [-0.61, -0.39]) and PPI-120 (SMD = -0.44, 95% CI = [-0.54, -0.33]). The sensitivity and meta-regression analysis showed that sample size, gender proportion, imbalance for gender, source of control group, and study continent were sources of heterogeneity (P < .05) for both PPI-60 and PPI-120 outcomes. Our findings confirm a global sensorimotor gating deficit in schizophrenia patients, with overall moderate effect size for PPI-60 and PPI-120. Methodological consistency should decrease the high level of heterogeneity of PPI results between studies.
Identifiants
pubmed: 32506125
pii: 5854327
doi: 10.1093/schbul/sbaa059
pmc: PMC8061122
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1482-1497Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Milbank Q. 2016 Sep;94(3):485-514
pubmed: 27620683
Biol Psychiatry. 2002 Nov 1;52(9):863-73
pubmed: 12399139
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58
pubmed: 11549226
Schizophr Res. 2004 Aug 1;69(2-3):219-35
pubmed: 15469195
Psychiatry Res. 2010 Jul 30;178(2):381-90
pubmed: 20483476
Schizophr Res. 2018 Aug;198:52-59
pubmed: 29287625
Neurosci Res. 2007 Sep;59(1):23-8
pubmed: 17692982
Br J Psychiatry. 2019 Feb;214(2):103-112
pubmed: 30139394
Biol Psychiatry. 2003 Jul 15;54(2):121-8
pubmed: 12873801
Arch Gen Psychiatry. 1992 Mar;49(3):206-15
pubmed: 1567275
Biol Psychiatry. 2005 Apr 1;57(7):817-20
pubmed: 15820241
Schizophr Bull. 2009 Jan;35(1):244-55
pubmed: 18245063
Schizophr Res. 2001 Apr 15;49(1-2):171-8
pubmed: 11343875
BMC Psychiatry. 2018 Aug 16;18(1):258
pubmed: 30115023
J Psychopharmacol. 2016 Nov;30(11):1072-1081
pubmed: 27539931
Psychophysiology. 2008 Sep;45(5):876-82
pubmed: 18665868
Schizophr Res. 2009 Dec;115(2-3):215-21
pubmed: 19846280
Neurosci Res. 2009 Nov;65(3):259-62
pubmed: 19660506
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Chin Med J (Engl). 2013 Feb;126(3):526-31
pubmed: 23422119
Arch Gen Psychiatry. 2012 Dec;69(12):1216-24
pubmed: 23026889
Front Behav Neurosci. 2016 Oct 18;10:202
pubmed: 27803654
Biol Psychiatry. 2001 Sep 15;50(6):418-24
pubmed: 11566158
Schizophr Res. 2012 May;137(1-3):203-11
pubmed: 22341200
Span J Psychol. 2016 Mar 03;19:E8
pubmed: 26936103
Psychiatry Res. 2011 Jul 30;188(2):208-16
pubmed: 21555157
Biol Psychiatry. 2000 Jan 1;47(1):61-70
pubmed: 10650450
Biol Psychiatry. 2008 Jan 1;63(1):17-23
pubmed: 17631867
Schizophr Res. 2018 Aug;198:28-35
pubmed: 28732798
Neuropsychiatr Dis Treat. 2016 Jan 06;12:57-67
pubmed: 26792993
Hum Psychopharmacol. 2013 May;28(3):220-9
pubmed: 23553665
Schizophr Res. 2007 Jan;89(1-3):225-31
pubmed: 17005374
Neurosci Biobehav Rev. 2009 Sep;33(8):1157-67
pubmed: 19747594
Arch Gen Psychiatry. 1999 Mar;56(3):277-81
pubmed: 10078506
Schizophr Res. 2008 Apr;101(1-3):185-94
pubmed: 18262774
Int J Neuropsychopharmacol. 2011 Aug;14(7):913-25
pubmed: 21294942
Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54
pubmed: 11549216
J Psychopharmacol. 1998;12(4):330-7
pubmed: 10065906
J Psychopharmacol. 2017 Aug;31(8):1035-1045
pubmed: 28648138
J Int Med Res. 2012;40(4):1467-75
pubmed: 22971498
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Am J Psychiatry. 1994 Mar;151(3):363-7
pubmed: 8109644
Cogn Neuropsychiatry. 2016;21(2):156-67
pubmed: 26982087
Biol Psychiatry. 2001 Feb 15;49(4):374-84
pubmed: 11239909
Pharmacopsychiatry. 2011 May;44(3):102-8
pubmed: 21432751
Swiss Med Wkly. 2002 Apr 6;132(13-14):159-65
pubmed: 12070788
Schizophr Bull. 2016 Nov;42(6):1504-1516
pubmed: 27217271
Biol Psychiatry. 2004 Mar 1;55(5):518-23
pubmed: 15023580
Dialogues Clin Neurosci. 2006;8(1):9-16
pubmed: 16640109
Schizophr Res. 2007 Mar;91(1-3):14-21
pubmed: 17276036
Schizophr Bull. 2019 Sep 11;45(5):1092-1100
pubmed: 30388260
Am J Psychiatry. 2002 Aug;159(8):1375-81
pubmed: 12153831
Psychophysiology. 2003 Sep;40(5):684-701
pubmed: 14696723
Psychiatry Res. 2006 Dec 7;145(2-3):137-45
pubmed: 17070928
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Schizophr Res. 2014 Feb;152(2-3):503-12
pubmed: 24405980
Dental Press J Orthod. 2014 Jul-Aug;19(4):27-9
pubmed: 25279518
Am J Psychiatry. 2002 Jun;159(6):1018-28
pubmed: 12042192
PLoS One. 2012;7(7):e39434
pubmed: 22802938
Biol Psychiatry. 2007 May 15;61(10):1204-7
pubmed: 17161386
Psychopharmacology (Berl). 2001 Jul;156(2-3):194-215
pubmed: 11549223
Psychophysiology. 2005 Jan;42(1):1-15
pubmed: 15720576
Schizophr Res. 2002 May 1;55(1-2):129-37
pubmed: 11955972
Psychophysiology. 1978 Jul;15(4):339-43
pubmed: 693742
Biol Psychiatry. 1998 Oct 15;44(8):739-47
pubmed: 9798078
Psychiatry Res. 2006 Dec 1;148(2-3):75-92
pubmed: 17088049
J Psychiatry Neurosci. 2013 Jan;38(1):34-42
pubmed: 22687247
Schizophr Res. 2018 Aug;198:6-15
pubmed: 28549722
Arch Gen Psychiatry. 2006 Dec;63(12):1325-35
pubmed: 17146007
Biol Psychiatry. 2002 Oct 1;52(7):729-39
pubmed: 12372664
Am J Psychiatry. 2007 Jan;164(1):61-5
pubmed: 17202545
Psychol Methods. 2006 Jun;11(2):193-206
pubmed: 16784338
Psychiatr Genet. 2005 Mar;15(1):61-5
pubmed: 15722959
Am J Psychiatry. 1999 Jul;156(7):1046-51
pubmed: 10401450
Acta Psychiatr Scand. 2015 Mar;131(3):185-96
pubmed: 25597383
Biol Psychiatry. 2006 Mar 15;59(6):536-45
pubmed: 16139819
Biol Psychiatry. 2000 Apr 1;47(7):662-9
pubmed: 10745060
J Nerv Ment Dis. 2016 Dec;204(12):877-884
pubmed: 27483114
Schizophr Res. 2005 Jul 1;76(1):1-23
pubmed: 15927795
Asian J Psychiatr. 2012 Mar;5(1):54-7
pubmed: 26878949
Psychiatry Res. 2014 Dec 15;220(1-2):535-40
pubmed: 25175914
Schizophr Res. 2011 Aug;130(1-3):1-10
pubmed: 21645998
J Clin Psychopharmacol. 2002 Aug;22(4):359-65
pubmed: 12172334
Mol Psychiatry. 2005 Feb;10(2):201-7
pubmed: 15263904
J Affect Disord. 2004 Aug;81(2):179-84
pubmed: 15306146
Neurosci Biobehav Rev. 2016 Aug;67:57-78
pubmed: 26743859
Front Neurosci. 2018 Sep 26;12:654
pubmed: 30319337
Int J Neuropsychopharmacol. 2010 Nov;13(10):1383-95
pubmed: 20633319
Schizophr Res. 2002 May 1;55(1-2):139-46
pubmed: 11955973
Psychiatry Res. 2011 May 30;187(3):324-8
pubmed: 21397338
J Psychiatr Res. 2016 Nov;82:155-62
pubmed: 27505440
Brain Res. 1996 May 25;722(1-2):168-76
pubmed: 8813362
J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):192-200
pubmed: 7876851
Psychophysiology. 2004 May;41(3):401-6
pubmed: 15102125
Neuropsychopharmacology. 2014 Dec;39(13):3000-8
pubmed: 24954063
Psychopharmacology (Berl). 2001 Jul;156(2-3):216-24
pubmed: 11549224
Schizophr Res. 2018 Aug;198:1-5
pubmed: 29525460
J Psychiatr Res. 2013 Apr;47(4):445-52
pubmed: 23287742
Behav Brain Res. 2005 Mar 7;158(1):159-66
pubmed: 15680203
Schizophr Bull. 2014 May;40(3):642-52
pubmed: 23599252
Biol Psychiatry. 1986 Jan;21(1):23-33
pubmed: 3080033
Schizophr Res. 2009 Jul;112(1-3):86-90
pubmed: 19423298
Psychiatry Res. 2010 Jul 30;178(2):236-43
pubmed: 20483176
Eur Arch Psychiatry Clin Neurosci. 2004 Dec;254(6):415-21
pubmed: 15538598
Psychiatry Res. 2012 Mar 30;196(1):1-8
pubmed: 22482796
J Psychiatr Res. 2005 May;39(3):227-40
pubmed: 15725421
Arch Gen Psychiatry. 2000 Jun;57(6):609-14
pubmed: 10839340
Neuromolecular Med. 2015 Dec;17(4):423-30
pubmed: 26376812
Am J Psychiatry. 1999 Apr;156(4):596-602
pubmed: 10200740
Psychiatry Res. 2007 May 30;151(1-2):21-8
pubmed: 17382404
Neurosci Res. 2008 Nov;62(3):187-94
pubmed: 18789980
Eur Psychiatry. 2011 Jul-Aug;26(5):271-5
pubmed: 20542668
Psychiatry Res. 2015 Aug 30;228(3):283-8
pubmed: 26154819
Eur Arch Psychiatry Clin Neurosci. 2010 Dec;260(8):609-15
pubmed: 20112025
Am J Psychiatry. 2000 Oct;157(10):1660-8
pubmed: 11007721
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120